| Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning (NCT01730781) | Yale University | 2010-07-01 |
| Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone (NCT01173874) | New York State Psychiatric Institute | 2010-07-01 |
| Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia (NCT01123317) | University of Maryland, Baltimore | 2010-07-01 |
| Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia (NCT01121042) | Bayside Health | 2010-07-01 |
| Antipsychotics and Gene Expression in Soft Tissues (NCT01185743) | Medical University of Vienna | 2010-07-01 |
| The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours (NCT01377896) | AstraZeneca | 2010-07-01 |
| Acute Glycine Pharmacodynamic Study (NCT01610011) | Mclean Hospital | 2010-07-01 |
| An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (NCT01129882) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-06-24 |
| Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis (NCT01196286) | University of Arizona | 2010-06-01 |
| The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia (NCT01167348) | TsaoTun Psychiatric Center, Department of Health, Taiwan | 2010-06-01 |
| Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study (NCT01133080) | Shalvata Mental Health Center | 2010-06-01 |
| A Long-Term, Open-Label, Study on Schizophrenia (NCT01129674) | Eli Lilly and Company | 2010-06-01 |
| Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia (NCT01082588) | Massachusetts General Hospital | 2010-06-01 |
| Effects of Ketamine and Risperidone on Cognition (NCT01140620) | University of Manchester | 2010-06-01 |
| How Reducing Anxiety in Schizophrenia (NCT02390271) | Institut de Recherche Biomedicale des Armees | 2010-06-01 |
| The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia (NCT01493622) | Central South University | 2010-06-01 |
| Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation (NCT00801567) | Mclean Hospital | 2010-06-01 |
| Different Safety Profile of Risperidone and Paliperidone Extended-release (NCT01284959) | Chonbuk National University Hospital | 2010-06-01 |
| A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (NCT01143077) | Sumitomo Pharma America, Inc. | 2010-06-01 |
| Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment (NCT06326840) | Taipei Medical University Hospital | 2010-05-31 |
| Long-term Study of Cariprazine in Patients With Schizophrenia (NCT01104792) | Forest Laboratories | 2010-05-31 |
| Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125) (NCT01142596) | Organon and Co | 2010-05-25 |
| 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124) (NCT01098110) | Organon and Co | 2010-05-25 |
| The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With Schizophrenia (NCT01139099) | National Taiwan University Hospital | 2010-05-01 |
| Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia (NCT00999505) | Hospital de Clinicas de Porto Alegre | 2010-05-01 |
| Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (NCT01804257) | Proteus Digital Health, Inc. | 2010-05-01 |
| Effects of Galantamine on Cognition (NCT01100775) | University of Maryland, Baltimore | 2010-05-01 |
| A Study in Schizophrenic Patients (NCT01125358) | Denovo Biopharma LLC | 2010-05-01 |
| Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia (NCT01324167) | Taipei Medical University WanFang Hospital | 2010-05-01 |
| The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients (NCT01186471) | Janssen Pharmaceutica N.V., Belgium | 2010-05-01 |
| Patient Guided Psychiatric Admissions (NCT01133587) | St. Olavs Hospital | 2010-05-01 |
| 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated (NCT01157351) | Janssen Scientific Affairs, LLC | 2010-05-01 |
| The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects. (NCT01181934) | Janssen Pharmaceutica N.V., Belgium | 2010-05-01 |
| Safety and Efficacy of Cariprazine in Schizophrenia (NCT01104779) | Forest Laboratories | 2010-04-27 |
| Safety and Efficacy of Cariprazine in Patients With Schizophrenia (NCT01104766) | Forest Laboratories | 2010-04-23 |
| GlyT-1 Inhibitor Treatment for Refractory Schizophrenia (NCT01251055) | China Medical University Hospital | 2010-04-01 |
| Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) (NCT01138618) | University of Aarhus | 2010-04-01 |
| Smoking Cessation for Veterans With Severe and Persistent Mental Illness (NCT00960375) | US Department of Veterans Affairs | 2010-04-01 |
| Zyprexa® Relprevv™ Patient Care Program (NCT01088386) | Eli Lilly and Company | 2010-03-03 |
| A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients (NCT01091506) | Pamlab, Inc. | 2010-03-01 |
| A Study in Schizophrenia Patients (NCT01086748) | Eli Lilly and Company | 2010-03-01 |
| A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs) (NCT00677898) | US Department of Veterans Affairs | 2010-03-01 |
| Database Registry for Neural Network Biomarkers in Psychosis (NCT01409109) | University of Texas Southwestern Medical Center | 2010-03-01 |
| The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan (NCT01170689) | TsaoTun Psychiatric Center, Department of Health, Taiwan | 2010-03-01 |
| Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia (NCT01093365) | Centre for Addiction and Mental Health | 2010-03-01 |
| Huperzine for Cognitive and Functional Impairment in Schizophrenia (NCT00963846) | Biomedisyn Corporation | 2010-03-01 |
| First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 (NCT02765555) | Indivior Inc. | 2010-03-01 |
| Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia (NCT01176721) | cerbomed GmbH | 2010-03-01 |
| Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (NCT01081769) | Janssen-Cilag International NV | 2010-02-01 |
| Imaging Cannabinoid CB1 Receptors in Schizophrenia (NCT01063335) | National Institute of Mental Health (NIMH) | 2010-02-01 |
| Ketamine Challenge Study With JNJ-40411813 (NCT01101659) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-02-01 |
| Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia (NCT01164059) | University of Bremen | 2010-02-01 |
| Is MS14 Helpful in Schizophrenia? (NCT01083381) | Farzan Institute | 2010-02-01 |
| Regulation of Arginine-vasopressin (AVP) (NCT02626832) | Yale University | 2010-02-01 |
| Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype (NCT01078870) | National Taiwan University Hospital | 2010-02-01 |
| Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia (NCT01012167) | University of Maryland, Baltimore | 2010-02-01 |
| Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis (NCT01570972) | University of Arizona | 2010-02-01 |
| Clinical Symptoms of Schizophrenia and Physical Exercise (NCT01674543) | Federal University of São Paulo | 2010-02-01 |
| Schizophrenia and Physical Exercise (NCT01595698) | Federal University of São Paulo | 2010-02-01 |
| A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia (NCT01232790) | Yale University | 2010-02-01 |
| Study of Vitamin D in the Severely Mentally Ill (NCT01169142) | Bronx Psychiatric Center | 2010-01-01 |
| A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms (NCT01052103) | Denovo Biopharma LLC | 2010-01-01 |
| Mental Healthcare in Older Adults With Schizophrenia (NCT02884739) | CHU de Reims | 2010-01-01 |
| DECIFER: Depression and Citalopram In First Episode Recovery (NCT01041274) | NYU Langone Health | 2010-01-01 |
| Nicotinic Receptors and Schizophrenia (NCT00952393) | VA Office of Research and Development | 2010-01-01 |
| The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia (NCT01045720) | Taichung Veterans General Hospital | 2010-01-01 |
| Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living (NCT02520024) | Temple University Collaborative on Community Inclusion | 2010-01-01 |
| Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study (NCT02201888) | Salvador Sarró, MD | 2010-01-01 |
| An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia (NCT01009047) | Janssen Research & Development, LLC | 2009-12-01 |
| Cannabis and Schizophrenia: Self-Medication and Agonist Treatment (NCT00946348) | Dartmouth-Hitchcock Medical Center | 2009-12-01 |
| Screening Protocol for Research Participants (NCT01010620) | University of Maryland, Baltimore | 2009-12-01 |
| Varenicline and Smoking Cessation in Schizophrenia (NCT01111149) | University of Minnesota | 2009-12-01 |
| Genes, Intermediate Phenotypes and Response to Quetiapine RX (NCT01044914) | University of Bari | 2009-12-01 |
| Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia (NCT00728728) | VA Office of Research and Development | 2009-12-01 |
| Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia (NCT01029769) | Technical University of Munich | 2009-12-01 |
| Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (NCT01009060) | GlaxoSmithKline | 2009-12-01 |
| Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia (NCT01012830) | VA Nebraska Western Iowa Health Care System | 2009-12-01 |
| Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography (NCT00942981) | National Institute of Mental Health (NIMH) | 2009-11-13 |
| Internal Monitoring of Eye Movement in Schizophrenia (NCT01011101) | National Eye Institute (NEI) | 2009-11-02 |
| Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention (NCT00980252) | University of Illinois at Chicago | 2009-11-01 |
| Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression (NCT01028196) | AstraZeneca | 2009-11-01 |
| Oxytocin Treatment of Schizophrenia (NCT01028677) | University of North Carolina, Chapel Hill | 2009-11-01 |
| Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia (NCT01043458) | Abbott | 2009-11-01 |
| Milestones of Adjustment Post-Psychosis (NCT01192594) | Yale University | 2009-11-01 |
| A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia (NCT00977522) | Pfizer | 2009-11-01 |
| Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (NCT00817154) | Dartmouth-Hitchcock Medical Center | 2009-11-01 |
| A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients (NCT00999895) | AstraZeneca | 2009-10-01 |
| The Effect of Ketamine on Attentiveness (NCT01165294) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-10-01 |
| Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study (NCT01269710) | University of North Carolina, Chapel Hill | 2009-10-01 |
| Cognitive Behavior Therapy and Work Outcome (NCT00810355) | VA Office of Research and Development | 2009-10-01 |
| TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia (NCT01003379) | Targacept Inc. | 2009-10-01 |
| Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. (NCT00716755) | Centre for Addiction and Mental Health | 2009-10-01 |
| Competence Ability Study in People With Schizophrenia (NCT01045629) | Taichung Veterans General Hospital | 2009-10-01 |
| Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (NCT00975611) | David C. Henderson, MD | 2009-10-01 |
| Lifestyle Modification for Weight Loss in Schizophrenia (NCT00990925) | Yale University | 2009-10-01 |
| Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis (NCT01003132) | University of Glasgow | 2009-10-01 |
| A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children (NCT01050582) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-10-01 |
| Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry (NCT00986167) | Bayside Health | 2009-10-01 |
| Effects of Oxytocin Nasal Spray on Social Affiliation (NCT00663039) | University of Maryland, Baltimore | 2009-10-01 |
| Auditory Verbal Hallucinations in Schizophrenia (NCT01886417) | University Hospital, Grenoble | 2009-10-01 |